Telix raises US$600m via new convertible notes to refinance 2029 bonds

An announcement from Telix Pharmaceuticals ( (AU:TLX) ) is now available.

Telix Pharmaceuticals has detailed the issuance of US$600 million in 1.50% senior unsecured convertible notes due 2031 via its wholly owned subsidiary, Telix Pharmaceuticals (Investments) Inc., with guarantees from Telix and its U.S. arm. The notes will be convertible into Telix ordinary shares and listed on the open market of the Singapore Exchange, targeting sophisticated and institutional investors in Australia and selected overseas markets.

The company plans to use the net proceeds to help repurchase its existing A$650 million convertible bonds due 2029 and for general corporate purposes, effectively refinancing its debt profile. Telix has obtained specific ASIC relief to allow shares issued on conversion of the new notes to be on‑sold without a prospectus, and notes that the new instruments will increase total liabilities by US$600 million initially but could reduce debt and expand the share base upon conversion, while enabling potential cancellation of all 2029 bonds if a sufficient portion is bought back.

The most recent analyst rating on (AU:TLX) stock is a Buy with a A$19.00 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.

More about Telix Pharmaceuticals

Telix Pharmaceuticals is an Australia-based radiopharmaceutical company focused on developing and commercializing diagnostic and therapeutic products for cancer and other serious diseases. The company is listed on the ASX and operates globally, including through its U.S. subsidiary Telix Pharmaceuticals (US) Inc., with a capital markets strategy that includes the use of convertible debt instruments.

YTD Price Performance: 32.14%

Average Trading Volume: 3,408,551

Technical Sentiment Signal: Buy

Current Market Cap: A$5.02B

See more insights into TLX stock on TipRanks’ Stock Analysis page.